PandemieGrippaleV1, PubMed, Corpus, bibRecord, 000749

Passive broad-spectrum influenza immunoprophylaxis.

Identifieur interne : 000749 ( PubMed/Corpus ); précédent : 000748; suivant : 000750

Passive broad-spectrum influenza immunoprophylaxis.

Auteurs : Cassandra M. Berry ; William J. Penhale ; Mark Y. Sangster

Source :

Influenza research and treatment [ 2090-1380 ] ; 2014.

RBID : pubmed:25328697

Abstract

Influenza is a perennial problem affecting millions of people annually with the everpresent threat of devastating pandemics. Active prophylaxis by vaccination against influenza virus is currently the main countermeasure supplemented with antivirals. However, disadvantages of this strategy include the impact of antigenic drift, necessitating constant updating of vaccine strain composition, and emerging antiviral drug resistance. The development of other options for influenza prophylaxis, particularly with broad acting agents able to provide protection in the period between the onset of a pandemic and the development of a strain specific vaccine, is of great interest. Exploitation of broad-spectrum mediators could provide barricade protection in the early critical phase of influenza virus outbreaks. Passive immunity has the potential to provide immediate antiviral effects, inhibiting virus replication, reducing virus shedding, and thereby protecting vulnerable populations in the event of an impending influenza pandemic. Here, we review passive broad-spectrum influenza prophylaxis options with a focus on harnessing natural host defenses, including interferons and antibodies.

DOI: 10.1155/2014/267594
PubMed: 25328697

Links to Exploration step

pubmed:25328697

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Passive broad-spectrum influenza immunoprophylaxis.</title>
<author><name sortKey="Berry, Cassandra M" sort="Berry, Cassandra M" uniqKey="Berry C" first="Cassandra M" last="Berry">Cassandra M. Berry</name>
<affiliation><nlm:affiliation>Molecular and Biomedical Sciences, School of Veterinary and Life Sciences, Murdoch University, Perth, WA 6150, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Penhale, William J" sort="Penhale, William J" uniqKey="Penhale W" first="William J" last="Penhale">William J. Penhale</name>
<affiliation><nlm:affiliation>Molecular and Biomedical Sciences, School of Veterinary and Life Sciences, Murdoch University, Perth, WA 6150, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sangster, Mark Y" sort="Sangster, Mark Y" uniqKey="Sangster M" first="Mark Y" last="Sangster">Mark Y. Sangster</name>
<affiliation><nlm:affiliation>Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:25328697</idno>
<idno type="pmid">25328697</idno>
<idno type="doi">10.1155/2014/267594</idno>
<idno type="wicri:Area/PubMed/Corpus">000749</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000749</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Passive broad-spectrum influenza immunoprophylaxis.</title>
<author><name sortKey="Berry, Cassandra M" sort="Berry, Cassandra M" uniqKey="Berry C" first="Cassandra M" last="Berry">Cassandra M. Berry</name>
<affiliation><nlm:affiliation>Molecular and Biomedical Sciences, School of Veterinary and Life Sciences, Murdoch University, Perth, WA 6150, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Penhale, William J" sort="Penhale, William J" uniqKey="Penhale W" first="William J" last="Penhale">William J. Penhale</name>
<affiliation><nlm:affiliation>Molecular and Biomedical Sciences, School of Veterinary and Life Sciences, Murdoch University, Perth, WA 6150, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sangster, Mark Y" sort="Sangster, Mark Y" uniqKey="Sangster M" first="Mark Y" last="Sangster">Mark Y. Sangster</name>
<affiliation><nlm:affiliation>Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Influenza research and treatment</title>
<idno type="ISSN">2090-1380</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Influenza is a perennial problem affecting millions of people annually with the everpresent threat of devastating pandemics. Active prophylaxis by vaccination against influenza virus is currently the main countermeasure supplemented with antivirals. However, disadvantages of this strategy include the impact of antigenic drift, necessitating constant updating of vaccine strain composition, and emerging antiviral drug resistance. The development of other options for influenza prophylaxis, particularly with broad acting agents able to provide protection in the period between the onset of a pandemic and the development of a strain specific vaccine, is of great interest. Exploitation of broad-spectrum mediators could provide barricade protection in the early critical phase of influenza virus outbreaks. Passive immunity has the potential to provide immediate antiviral effects, inhibiting virus replication, reducing virus shedding, and thereby protecting vulnerable populations in the event of an impending influenza pandemic. Here, we review passive broad-spectrum influenza prophylaxis options with a focus on harnessing natural host defenses, including interferons and antibodies. </div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">25328697</PMID>
<DateCompleted><Year>2014</Year>
<Month>10</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2090-1380</ISSN>
<JournalIssue CitedMedium="Print"><Volume>2014</Volume>
<PubDate><Year>2014</Year>
</PubDate>
</JournalIssue>
<Title>Influenza research and treatment</Title>
<ISOAbbreviation>Influenza Res Treat</ISOAbbreviation>
</Journal>
<ArticleTitle>Passive broad-spectrum influenza immunoprophylaxis.</ArticleTitle>
<Pagination><MedlinePgn>267594</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/267594</ELocationID>
<Abstract><AbstractText>Influenza is a perennial problem affecting millions of people annually with the everpresent threat of devastating pandemics. Active prophylaxis by vaccination against influenza virus is currently the main countermeasure supplemented with antivirals. However, disadvantages of this strategy include the impact of antigenic drift, necessitating constant updating of vaccine strain composition, and emerging antiviral drug resistance. The development of other options for influenza prophylaxis, particularly with broad acting agents able to provide protection in the period between the onset of a pandemic and the development of a strain specific vaccine, is of great interest. Exploitation of broad-spectrum mediators could provide barricade protection in the early critical phase of influenza virus outbreaks. Passive immunity has the potential to provide immediate antiviral effects, inhibiting virus replication, reducing virus shedding, and thereby protecting vulnerable populations in the event of an impending influenza pandemic. Here, we review passive broad-spectrum influenza prophylaxis options with a focus on harnessing natural host defenses, including interferons and antibodies. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berry</LastName>
<ForeName>Cassandra M</ForeName>
<Initials>CM</Initials>
<AffiliationInfo><Affiliation>Molecular and Biomedical Sciences, School of Veterinary and Life Sciences, Murdoch University, Perth, WA 6150, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Penhale</LastName>
<ForeName>William J</ForeName>
<Initials>WJ</Initials>
<AffiliationInfo><Affiliation>Molecular and Biomedical Sciences, School of Veterinary and Life Sciences, Murdoch University, Perth, WA 6150, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sangster</LastName>
<ForeName>Mark Y</ForeName>
<Initials>MY</Initials>
<AffiliationInfo><Affiliation>Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>09</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Influenza Res Treat</MedlineTA>
<NlmUniqueID>101576388</NlmUniqueID>
<ISSNLinking>2090-1380</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>07</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>09</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25328697</ArticleId>
<ArticleId IdType="doi">10.1155/2014/267594</ArticleId>
<ArticleId IdType="pmc">PMC4190013</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Vaccine. 1996 Jan;14(1):85-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8821654</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Tissue Res. 2011 Jan;343(1):13-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20848130</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharm Res. 2000 Mar;17(3):275-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10801215</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Immunol. 2009 Dec;30(12):574-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19864182</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Rev. 2013 Sep;255(1):25-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23947345</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2013 Sep;7(5):854-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23398960</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hyg (Lond). 1984 Apr;92(2):231-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6707472</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2010 Aug;11(8):681-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20644574</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2010 May;120(5):1663-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20389023</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013 Apr 09;8(4):e61504</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23585906</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2014 Feb 27;370(9):789-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24450860</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2008 Jun 6;26(24):3055-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18241960</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2014 Apr;12(4):252-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24590244</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2013 May 23;497(7450):498-502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23636320</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Apr;87(8):4728-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23408625</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2008;3(12):e3942</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19079604</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2008 Aug 1;47(3):401-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18558875</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2010 Dec;88(3):249-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20849879</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2009 Jan;37(Database issue):D852-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18996892</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2012 Oct;86(19):10359-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22787226</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2009 Sep;53(9):3935-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19596886</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2009 Dec 15;200(12):1870-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19911992</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2006 Jan;24(1):5-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16413916</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2014 Feb;20(2):143-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24412922</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Virol. 2014 Oct;8:22-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24866471</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care Med. 2010 Apr;38(4 Suppl):e66-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20154602</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2011 Feb 15;52(4):447-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21248066</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viral Immunol. 2010 Jun;23(3):321-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20565295</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2013 Jun;98(3):476-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23583287</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gene Med. 2011 Jan;13(1):60-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21259409</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int Immunopharmacol. 2011 Dec;11(12):2000-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21906698</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2014 Jan;15(1):3-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24352315</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Pharmacol. 1972 Feb 15;21(4):503-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4111355</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2009 Sep 1;183(5):3294-301</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19648276</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2012 Jul 26;55(14):6263-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22612288</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2010 Oct;88(1):64-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20659503</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Sci Tech. 2009 Apr;28(1):187-202</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19618626</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2013 Nov;100(2):446-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24084488</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 Mar;88(6):3432-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24403585</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Interferon Cytokine Res. 2014 Jun;34(6):455-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24905202</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antivir Ther. 2008;13(3):409-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18572754</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 2010 Apr;155(4):491-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20195655</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 1998 Feb 1;101(3):643-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9449698</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 1998 Jun 15;58(12):2489-99</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9635566</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014 Feb 28;9(2):e89674</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24586955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2012 Nov 14;4(11):3090-108</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23202517</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2003 Jul 4;21(23):3212-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12804850</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1983 Jun;127(2):361-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6868370</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer. 2001 Sep 15;92(6 Suppl):1664-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11598884</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):425-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17683972</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Pharm. 2003 Mar 18;254(1):43-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12615407</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Feb 25;27(9):1354-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19150474</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 Apr 24;58(15):400-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19390508</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2011 Apr 1;186(7):3823-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21422252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2009 Apr 10;324(5924):246-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19251591</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Oct;87(19):10435-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23903831</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2011 Sep 16;146(6):980-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21925319</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunology. 1988 Mar;63(3):349-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2832312</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neuroscience. 2008 Mar 27;152(3):785-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18304744</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(8):e42363</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22879951</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2007 May 15;104(20):8269-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17494769</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Biotechnol Biochem. 2012;76(3):581-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22451404</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Subcell Biochem. 2010;54:228-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21222286</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010 Oct 26;5(10):e13622</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21049034</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunotherapy. 2012 Feb;4(2):175-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22339460</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Interferon Cytokine Res. 1999 Apr;19(4):295-308</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10334380</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2010 Aug 27;329(5995):1060-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20647428</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2007 Oct 4;357(14):1450-1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17914053</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Hypotheses. 2009 Jan;72(1):74-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18824305</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2012 Jun;93(Pt 6):1269-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22377585</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Jun;84(11):5670-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20335250</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2014 Jan;14(1):57-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24239327</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Peptides. 2011 Jul;32(7):1518-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21620914</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2009 Feb 1;182(3):1296-304</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19155475</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2573-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22308500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2014 Apr 29;6(5):1974-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24784572</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2009 Nov 12;361(20):1945-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19745214</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1966 Aug;97(2):177-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5921310</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2003 Aug;47(8):2518-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12878514</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2011 Apr;55(4):1349-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21245446</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Exp Immunol. 1998 Mar;111(3):583-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9528903</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Immunol. 2014 Feb;44(2):397-408</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24222381</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2009 Feb 6;136(3):402-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19203576</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunology. 1994 Feb;81(2):280-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8157277</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010 Feb 08;5(2):e9106</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20161706</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2012 May 02;486(7403):420-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22722205</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care Med. 2012 Mar;40(3):1027-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22343871</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 1999 Oct;5(10):1157-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10502819</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(3):e34377</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22457834</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2014 Sep 18;371(12):1086-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25140857</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2010 Oct 10;406(1):80-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20667572</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care Med. 2012 Mar;40(3):973-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22001587</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2010 Jan 15;327(5963):291-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20075244</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Feb 26;25(10):1856-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17240000</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Jul;81(13):7011-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17442719</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2006 Jan;12(1):15-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16494711</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000749 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000749 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:25328697
   |texte=   Passive broad-spectrum influenza immunoprophylaxis.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:25328697" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a PandemieGrippaleV1

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Passive broad-spectrum influenza immunoprophylaxis.

Passive broad-spectrum influenza immunoprophylaxis.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki